Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Finished Goods: 2020-2025

Historic Finished Goods for Puma Biotechnology (PBYI) over the last 4 years, with Sep 2025 value amounting to $439,000.

  • Puma Biotechnology's Finished Goods fell 3.94% to $439,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $439,000, marking a year-over-year decrease of 3.94%. This contributed to the annual value of $783,000 for FY2024, which is 38.10% up from last year.
  • Per Puma Biotechnology's latest filing, its Finished Goods stood at $439,000 for Q3 2025, which was down 42.39% from $762,000 recorded in Q2 2025.
  • In the past 5 years, Puma Biotechnology's Finished Goods ranged from a high of $1.6 million in Q1 2022 and a low of $186,000 during Q4 2022.
  • Its 3-year average for Finished Goods is $651,455, with a median of $618,000 in 2023.
  • As far as peak fluctuations go, Puma Biotechnology's Finished Goods crashed by 83.90% in 2022, and later spiked by 204.84% in 2023.
  • Over the past 5 years, Puma Biotechnology's Finished Goods (Quarterly) stood at $1.2 million in 2021, then crashed by 83.90% to $186,000 in 2022, then soared by 204.84% to $567,000 in 2023, then soared by 38.10% to $783,000 in 2024, then fell by 3.94% to $439,000 in 2025.
  • Its Finished Goods was $439,000 in Q3 2025, compared to $762,000 in Q2 2025 and $561,000 in Q1 2025.